Argenx announces positive topline phase 3 data from adapt-sc study evaluating subcutaneous efgartigimod for generalized myasthenia gravis

Breda, the netherlands--(business wire)--argenx announces positive topline phase 3 data from adapt-sc study evaluating subcutaneous efgartigimod for generalized myasthenia gravis

ARGX Ratings Summary

ARGX Quant Ranking